- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
VIVO Market Currents
more »
-
April 26 Meridian Bioscience (VIVO): FQ2 EPS of $0.23 beats by $0.02. Revenue of $47.4M (+15.3% Y/Y) beats by $3M. (PR)
Comment![Earnings, Healthcare]
VIVO in Focus
more »
VIVO Related Articles
more »
VIVO News
more »
-
at MarketWatch.com (Jul 21, 2011)
-
at CNBC.com (Dec 6, 2010)
VIVO Press Releases and Filings
more »
-
Business Wire (Apr 26, 2012)
-
Business Wire (Apr 12, 2012)
-
Business Wire (Apr 12, 2012)
-
Business Wire (Mar 21, 2012)
-
Business Wire (Mar 20, 2012)
VIVO Latest Transcript
more »
Currently, there are no transcripts for VIVO.
VIVO Cramer
more »
-
Tue, Dec 7, 2010
-
Thu, Aug 6, 2009
-
Mon, Sep 17, 2007
VIVO Instablog posts
more »
VIVO vs. ETF Alternatives
Company Description
Meridian is a fully-integrated life science company whose principal businesses are (i) the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain respiratory, gastrointestinal, viral and parasitic infectious diseases, (ii) the manufacture and distribution... More